Di Silverio F - Search Results

1

Benign prostatic hyperplasia: what about a campaign for prevention?

Di Silverio F, Gentile V, Pastore AL, Voria G, Mariotti G, Sciarra A. Di Silverio F, et al. Urol Int. 2004;72(3):179-88. doi: 10.1159/000077112. Urol Int. 2004. PMID: 15084759 Review.

2

Histopathological aspects associated with the diagnosis of benign prostatic hyperplasia: clinical implications.

Sciarra A, Voria G, Mariotti G, Gentile V, Pastore A, Di Silverio F. Sciarra A, et al. Among authors: di silverio f. Urol Int. 2002;69(4):253-62. doi: 10.1159/000066128. Urol Int. 2002. PMID: 12444279 Review. No abstract available.

3

Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.

Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Di Silverio F, et al. Eur Urol. 2003 Feb;43(2):164-75. doi: 10.1016/s0302-2838(02)00548-1. Eur Urol. 2003. PMID: 12565775

4

Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10.

Sciarra A, Gentile V, Voria G, Mariotti G, Seccareccia F, Pastore A, Di Silverio F. Sciarra A, et al. Among authors: di silverio f. Urol Int. 2003;70(3):186-94. doi: 10.1159/000068777. Urol Int. 2003. PMID: 12660455

5

Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.

Sciarra A, Cardi A, Di Silverio F. Sciarra A, et al. Among authors: di silverio f. Urol Int. 2004;72(2):91-8. doi: 10.1159/000075960. Urol Int. 2004. PMID: 14963347 Review.

6

Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.

Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F. Sciarra A, et al. Among authors: di silverio f. Urol Int. 2008;80(1):68-73. doi: 10.1159/000111733. Epub 2008 Jan 18. Urol Int. 2008. PMID: 18204237

7

Safety profile of selective alpha-1 adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.

Sciarra A, Di Silverio F. Sciarra A, et al. Among authors: di silverio f. Minerva Urol Nefrol. 1997 Mar;49(1):21-8. Minerva Urol Nefrol. 1997. PMID: 9099057

8

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.

Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F. Sciarra A, et al. Among authors: di silverio f. Prostate. 2003 May 15;55(3):168-79. doi: 10.1002/pros.10222. Prostate. 2003. PMID: 12692782 Clinical Trial.

9

Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.

Di Silverio F, Sciarra A. Di Silverio F, et al. J Urol. 2003 Nov;170(5):1812-6. doi: 10.1097/01.ju.0000092480.71873.26. J Urol. 2003. PMID: 14532782

10

Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.

Sciarra A, Bosman C, Monti G, Gentile V, Autran Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F. Sciarra A, et al. Among authors: di silverio f. J Urol. 2004 Nov;172(5 Pt 1):1775-83. doi: 10.1097/01.ju.0000140875.07255.f5. J Urol. 2004. PMID: 15540720 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters